Barbara Hendrickson to Humans
This is a "connection" page, showing publications Barbara Hendrickson has written about Humans.
Connection Strength
0.119
-
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci. 2024 07; 58(4):579-590.
Score: 0.028
-
Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation. Pharm Stat. 2022 03; 21(2):372-385.
Score: 0.023
-
Aggregate IND Safety Reporting for Smaller Companies and Programs. Ther Innov Regul Sci. 2024 03; 58(2):368-379.
Score: 0.007
-
Gastric inflammation as a feature of ulcerative colitis. J Pediatr Gastroenterol Nutr. 2003 Sep; 37(3):228-9.
Score: 0.007
-
Assessing adverse events in clinical trials during the era of the COVID-19 pandemic. J Biopharm Stat. 2023 07 04; 33(4):466-475.
Score: 0.006
-
MMR vaccination, ileal lymphoid nodular hyperplasia, and pervasive develop-mental disorder. Lancet. 2002 Jun 15; 359(9323):2051-2.
Score: 0.006
-
Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 Jan; 15(1):79-94.
Score: 0.006
-
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 06 05; 397(10290):2169-2181.
Score: 0.006
-
Interdisciplinary Safety Evaluation for Learning and Decision-Making. Ther Innov Regul Sci. 2021 07; 55(4):705-716.
Score: 0.006
-
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 03; 80(3):304-311.
Score: 0.005
-
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Ther Innov Regul Sci. 2020 03; 54(2):447-461.
Score: 0.005
-
A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. Ther Innov Regul Sci. 2020 07; 54(4):821-830.
Score: 0.005
-
RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 a1 and a2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017 06; 34(6):1364-1381.
Score: 0.004
-
Local vaccine site reactions and contact allergy to aluminum. Pediatr Dermatol. 2012 Jan-Feb; 29(1):68-72.
Score: 0.003
-
Protective role of HSP72 against Clostridium difficile toxin A-induced intestinal epithelial cell dysfunction. Am J Physiol Cell Physiol. 2003 Apr; 284(4):C1073-82.
Score: 0.002